Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Mar 08, 2023 7:01pm

125 Views

Post# 35327085

AGN holding SP gains

Algernon Pharmaceuticals Inc. (AGN.c AGNPF) closed stable today. Overall AGN has held most of the SP gains that it has made this week.

Currently, the pharma-tech company is studying DMT for the treatment of stroke and it plans to start a complementary study of DMT for the treatment of Traumatic Brain Injury later this year.

AGN has already hired multiple TBI experts to advise the DMT-TBI study

https://www.bctechnology.com/news/2023/3/8/Algernon-NeuroScience-Appoints-Global-TBI-Expert-and-Former-NFL-Neurological-Player-Care-Safety-Director-Dr.-David-Brody-to-Advisory-Board.cfm

<< Previous

Bullboard Posts

Next >>

Desert Gold Ventures - A jewel for the investor?